Per Lindblom
Global Products Manager, GMD
I am a Project leader at our CVRM (Cardiovascular, Renal and Metabolic Diseases) IMED biotech unit.
My main responsibilities are to lead the team who currently collaborate with biopharma company IONIS to create a new target to LOID, a project with the potential to impact on several features of type 2 diabetes. I am also Global Products Manager for one prominent program within type 2 diabetes, as well as for a pharmaceutical treating high cholesterol and preventing cardiovascular disease.
Being part of the IMED Biotech unit and a world class late stage project management organization at AstraZeneca is an opportunity for me to grow both as a scientist and as project leader. Collaborating with partners, such as IONIS, offers new approaches to treatments in well-known therapy areas. Creating paradigm shifts in the treatments of Cardiovascular, Renal and Metabolic Diseases really challenge us as professionals, and has great benefit for the medical society and patients alike. That´s why I am part of it all.
